Revolutionizing COPD Treatment: Inhaled Small Mobile Stem Cells for Lung Regeneration
Chronic Obstructive Pulmonary Disease (COPD) affects over 400 million people worldwide and remains incurable, with existing therapies focusing primarily on symptom management rather than tissue repair. Small Mobile Stem (SMS) cells represent a first-in-class, inhaled regenerative therapy that directly targets lung damage by stimulating alveolar repair, modulating inflammation, and enhancing antimicrobial defenses. Delivered via a patient-friendly nebulizer, SMS cells offer a scalable, off-the-shelf solution designed for broad COPD populations—including those unresponsive to current biologics. Preclinical studies demonstrate structural lung restoration, reduced inflammation, and protection against infection-driven exacerbations, positioning SMS cells as a potential disease-modifying treatment.
Dive deeper into the science and clinical potential of SMS cell therapy in COPD.
